Physician profile
Sudhakar Ancha
NPI 1346395852
$6,253.71
in general payments reported to CMS, 2019-2025
34 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $223 · 2021: $933 · 2022: $825 · 2023: $1,343 · 2024: $1,056 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689 · Education: $57.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.60 |
| Education | $57.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,023.98 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $804.70 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $517.36 | 2019-2025 | |
| Celgene Corporation | $353.61 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $344.41 | 2021-2025 | Stelara, Simponi, Remicade |
| Gilead Sciences, INC. | $295.11 | 2019-2025 | |
| Madrigal Pharmaceuticals | $268.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $167.54 | 2021-2024 | Linzess |
| Ambu INC. | $167.04 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $149.07 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $99.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.19 | 2020-2025 | Eohilia |
| Nestle Healthcare Nutrition INC. | $94.31 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $91.86 | 2024 | |
| Boston Scientific Corporation | $83.19 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $77.52 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $77.41 | 2019-2021 | |
| Echosens North America, INC. | $72.25 | 2025 | Fibroscan |
| Janssen Scientific Affairs, LLC | $68.06 | 2021 | |
| Braintree Laboratories, INC. | $41.53 | 2021 | |
| Capsovision, INC. | $37.90 | 2023-2024 | Capsocam Plus |
| Phathom Pharmaceuticals, INC. | $37.46 | 2025 | Voquezna |
| Baxter Healthcare | $34.99 | 2022 | |
| Welch Allyn | $34.99 | 2021 | |
| Merck Sharp & Dohme LLC | $30.49 | 2021-2023 | Dificid |
| Olympus America INC. | $28.96 | 2024 | Olympus |
| Alfasigma USA, INC. | $24.07 | 2020 | |
| Amgen INC. | $23.00 | 2023 | Amjevita |
| Novo Nordisk INC | $22.19 | 2025 | Wegovy |
| Celltrion USA INC. | $22.18 | 2025 | Vegzelma |
| Ardelyx, INC. | $18.90 | 2024 | Ibsrela |
| Qol Medical, LLC | $18.80 | 2024 | Sucraid |
| Sandoz INC. | $15.69 | 2024 | Hyrimoz |
| Allergan, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhakar Ancha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.